Denali Therapeutics Inc. Income Statement
DNLI / Health Care|10 years of annual SEC 10-K data (FY2016-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 10 fiscal years. All figures from audited SEC 10-K filings.
Denali Therapeutics Inc. reported $0 in revenue and $513M in net loss for FY2025. Revenue has grown at a 36.8% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.73 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $330.5M | $335.7M | $26.7M | $129.2M | $0 | $0 | $0 | $0 |
| SG&A Expense | $136.6M | $105.4M | $103.4M | $60.3M | $46.5M | $32.3M | $15.7M | $11.7M | $15.7M | $11.7M |
| R&D Expense | $418.8M | $396.4M | $423.9M | $212.6M | $193.4M | $143.2M | $74.5M | $75.7M | $74.5M | $75.7M |
| Operating Income | -$555.3M | -$487.3M | -$196.7M | $62.7M | -$213.2M | -$46.4M | -$90.1M | -$87.4M | -$90.1M | -$87.4M |
| Income Tax | $102.0K | $68.0K | $30.0K | $823.0K | -$351.0K | $0 | $0 | - | $0 | - |
| Net Income | -$512.5M | -$422.8M | -$145.2M | $71.1M | -$197.6M | -$36.2M | -$88.2M | -$86.7M | -$88.2M | -$86.7M |
| EPS (Basic) | -$1.06 | -$2.60 | -$2.39 | $0.65 | -$2.07 | -$0.39 | - | -$0.26 | - | - |
| EPS (Diluted) | -$1.06 | -$2.60 | -$2.39 | $0.63 | -$2.07 | -$0.39 | -$5.89 | -$0.26 | - | - |
| Shares Outstanding | 144.2M | 138.4M | 136.0M | 122.3M | 120.5M | 96.2M | 94.7M | 87.5M | 15.0M | 6.4M |
| Operating Margin | - | - | -59.5% | 18.7% | -799.1% | -35.9% | - | - | - | - |
| Profit Margin | - | - | -43.9% | 21.2% | -740.7% | -28.1% | - | - | - | - |